CDSCO panel approves Oxford COVID-19 vaccine for emergency use

New Delhi: An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has approved the emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India.

The Pune-based Serum Institute of India (SII), the world’s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday had approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.

The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which had earlier sought additional safety and immunogenicity data from SII, deliberated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday, and met again on Friday to review the matter.

More details to be added